Cipla surges on getting USFDA`s approval for Generic Advair Diskus
Cipla is currently trading at Rs. 1440.40, up by 30.55 points or 2.17% from its previous closing of Rs. 1409.85 on the BSE.
The scrip opened at Rs. 1425.10 and has touched a high and low of Rs. 1447.25 and Rs. 1425.10 respectively. So far 44184 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1165.55 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1,447.25 and Rs. 1366.20 respectively. The current market cap of the company is Rs. 116135.84 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.83% and 15.95% respectively.
Cipla has received U.S. Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three strengths-100/50 mcg, 250/50 mcg, and 500/50 mcg.
The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). According to IQVIA, the U.S. market for fluticasone propionate and salmeterol inhalation powder is around $908 million. This approval represents Cipla’s first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network, marking a significant step in the company’s continued expansion of complex respiratory capabilities in the United States.
Backed by Cipla’s vertically integrated inhalation platform, the product reflects the company’s commitment to strengthening U.S. manufacturing capabilities for complex respiratory treatments.
